NCT04141579 - Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

November 9, 2023

Study Completion Date

November 9, 2023

Conditions

Coronary Artery DiseaseAtherosclerosis of Coronary Artery

Interventions

DRUG

Evolocumab 140 MG/ML [Repatha]

Evolocumab (also known as Repatha, formerly referred to as AMG 145) is a human monoclonal immunoglobulin G2 (IgG2) that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) preventing its interaction with the low-density lipoprotein receptor (LDLR). The inhibition of PCSK9 by evolocumab leads to increased LDLR expression and subsequent decreased circulating concentrations of low-density lipoprotein cholesterol (LDL-C).

DRUG

Placebo

Matching placebo

Trial Locations (1)

6525 GA

Radboud University Medical Center, Nijmegen